All IndicationsMetabolic & EndocrineApprovedApprovedPhase 3Phase 3Phase 2Phase 2
⚡
Type 2 Diabetes
3
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
LLY
Eli Lilly
Onswik
LLY
Eli Lilly and Company
insulin efsitora alfa-gobe
LLY
Eli Lilly and Company
Insulin Efsitora Alfa
LLY
Eli Lilly
retatrutide
IONS
Ionis Pharmaceuticals, Inc.
ISIS-GCGRRx- Dose Level 1
INCY
Incyte Corporation
INCB013739
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly | Onswik | Approved | — | — | — |
| LLY Eli Lilly and Company | insulin efsitora alfa-gobe | Approved | — | — | — |
| LLY Eli Lilly and Company | Insulin Efsitora Alfa | Phase 3 | — | — | — |
| LLY Eli Lilly | retatrutide | Phase 3 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS-GCGRRx- Dose Level 1 | Phase 2 | — | — | — |
| INCY Incyte Corporation | INCB013739 | Phase 2 | — | — | — |
Development Stage Distribution
Approved
2
Phase 3
2
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.